NASDAQ:HALO Halozyme Therapeutics Q3 2026 Earnings Report $109.85 +1.54 (+1.42%) As of 09:38 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Halozyme Therapeutics EPS ResultsActual EPSN/AConsensus EPS $2.25Beat/MissN/AOne Year Ago EPSN/AHalozyme Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$482.28 millionBeat/MissN/AYoY Revenue GrowthN/AHalozyme Therapeutics Announcement DetailsQuarterQ3 2026Date11/2/2026TimeAfter Market ClosesConference Call DateMonday, November 2, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Halozyme Therapeutics Earnings HeadlinesHalozyme Therapeutics Insider Sold Shares Worth $567,661, According to a Recent SEC FilingOctober 3 at 7:06 AM | marketscreener.comMHalozyme Therapeutics (NASDAQ:HALO) Director Matthew Posard Sells 5,230 Shares of Company StockOctober 3 at 5:38 AM | americanbankingnews.comDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concerns about government authority to freeze or seize private accounts. Greece raided pensions. Cyprus drained bank accounts. Poland seized retirement funds. Priority Gold has put together a free Wealth Defense Guide for Americans looking to move assets beyond potential government reach.October 6 at 1:00 AM | Priority Gold (Ad)Unpacking Q2 earnings: Halozyme Therapeutics (NASDAQ:HALO) in the context of other therapeutics stocksOctober 1, 2026 | msn.comHalozyme Therapeutics, Inc. Appoints James "Jim" Daly to Its Board of DirectorsOctober 1, 2026 | marketscreener.comMHalozyme Therapeutics Adds James Daly to BoardSeptember 30, 2026 | tipranks.comSee More Halozyme Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Halozyme Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Halozyme Therapeutics and other key companies, straight to your email. Email Address About Halozyme TherapeuticsHalozyme Therapeutics (NASDAQ:HALO) is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection. Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies. Products using the company’s technology include subcutaneous formulations of several commercially available treatments, such as DARZALEX FASPRO, PHESGO, VYVGART HYTRULO and HyQvia. Halozyme also markets HYLENEX recombinant, a standalone hyaluronidase product used to facilitate the absorption and dispersion of other injected medicines and fluids. Founded in 1998 and headquartered in San Diego, California, Halozyme serves international markets primarily through licensing, collaboration and commercialization agreements with healthcare companies. Its business model combines technology partnerships, milestone payments and royalties tied to products that use its drug-delivery platforms.View Halozyme Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
